Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium.

2.50
Hdl Handle:
http://hdl.handle.net/10541/76856
Title:
Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium.
Authors:
Whitworth, Melissa K; Backen, Alison C; Clamp, Andrew R; Wilson, Godfrey E; McVey, Rhona J; Friedl, Andreas; Rapraeger, Alan C; David, Guido; McGown, Alan T; Slade, Richard J; Gallagher, John T; Jayson, Gordon C ( 0000-0002-8515-8944 )
Abstract:
Fibroblast growth factor-2 (FGF-2) is a potent angiogenic cytokine that is dependent on heparan sulfate for its biological activity. We have investigated the relationship among heparan sulfate, FGF-2, and the signal-transducing receptors in human, advanced-stage, serous ovarian adenocarcinoma. Using a unique molecular probe, FR1c-Ap, which consisted of a soluble FGF receptor 1 isoform IIIc covalently linked to an alkaline phosphatase moiety, the distribution of heparan sulfate that had the ability to support the formation of a heparan sulfate/FGF-2/FGFR1 isoform IIIc alkaline phosphatase heparan sulfate construct complex was determined. This may be taken as a surrogate marker for the distribution of biologically active heparan sulfate and was distributed predominantly in endothelial cells and stroma but was absent from adenocarcinoma cells. In situ hybridization revealed the expression of FGFR1 mRNA in the endothelium and reverse transcription-PCR confirmed the presence of FGFR1 isoform IIIc but not isoform IIIb. The presence of FGF-2 around tumor endothelium was detected through immunohistochemistry. Double-staining techniques showed that heparan sulfate was found predominantly at the basal aspect of the endothelium and suggested that syndecan-3 might function as one of the proteoglycans involved in FGF-2 signaling in the endothelium. The data suggest that the entire extracellular signaling apparatus, consisting of FGF-2, biologically active heparan sulfate, and FGFRs capable of responding to FGF-2, is present in ovarian cancer endothelium, thereby highlighting the cytokine and its cognate receptor as potential targets for the antiangiogenic treatment of this disease.
Affiliation:
Cancer Research UK Department of Medical Oncology, Christie Hospital and Paterson Institute, Manchester, United Kingdom.
Citation:
Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium. 2005, 11 (12):4282-8 Clin. Cancer Res.
Journal:
Clinical Cancer Research
Issue Date:
15-Jun-2005
URI:
http://hdl.handle.net/10541/76856
DOI:
10.1158/1078-0432.CCR-04-1386
PubMed ID:
15958608
Type:
Article
Language:
en
ISSN:
1078-0432
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorWhitworth, Melissa K-
dc.contributor.authorBacken, Alison C-
dc.contributor.authorClamp, Andrew R-
dc.contributor.authorWilson, Godfrey E-
dc.contributor.authorMcVey, Rhona J-
dc.contributor.authorFriedl, Andreas-
dc.contributor.authorRapraeger, Alan C-
dc.contributor.authorDavid, Guido-
dc.contributor.authorMcGown, Alan T-
dc.contributor.authorSlade, Richard J-
dc.contributor.authorGallagher, John T-
dc.contributor.authorJayson, Gordon C-
dc.date.accessioned2009-08-10T17:27:54Z-
dc.date.available2009-08-10T17:27:54Z-
dc.date.issued2005-06-15-
dc.identifier.citationRegulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium. 2005, 11 (12):4282-8 Clin. Cancer Res.en
dc.identifier.issn1078-0432-
dc.identifier.pmid15958608-
dc.identifier.doi10.1158/1078-0432.CCR-04-1386-
dc.identifier.urihttp://hdl.handle.net/10541/76856-
dc.description.abstractFibroblast growth factor-2 (FGF-2) is a potent angiogenic cytokine that is dependent on heparan sulfate for its biological activity. We have investigated the relationship among heparan sulfate, FGF-2, and the signal-transducing receptors in human, advanced-stage, serous ovarian adenocarcinoma. Using a unique molecular probe, FR1c-Ap, which consisted of a soluble FGF receptor 1 isoform IIIc covalently linked to an alkaline phosphatase moiety, the distribution of heparan sulfate that had the ability to support the formation of a heparan sulfate/FGF-2/FGFR1 isoform IIIc alkaline phosphatase heparan sulfate construct complex was determined. This may be taken as a surrogate marker for the distribution of biologically active heparan sulfate and was distributed predominantly in endothelial cells and stroma but was absent from adenocarcinoma cells. In situ hybridization revealed the expression of FGFR1 mRNA in the endothelium and reverse transcription-PCR confirmed the presence of FGFR1 isoform IIIc but not isoform IIIb. The presence of FGF-2 around tumor endothelium was detected through immunohistochemistry. Double-staining techniques showed that heparan sulfate was found predominantly at the basal aspect of the endothelium and suggested that syndecan-3 might function as one of the proteoglycans involved in FGF-2 signaling in the endothelium. The data suggest that the entire extracellular signaling apparatus, consisting of FGF-2, biologically active heparan sulfate, and FGFRs capable of responding to FGF-2, is present in ovarian cancer endothelium, thereby highlighting the cytokine and its cognate receptor as potential targets for the antiangiogenic treatment of this disease.en
dc.language.isoenen
dc.subjectOvarian Canceren
dc.subject.meshAlkaline Phosphatase-
dc.subject.meshEndothelium-
dc.subject.meshFemale-
dc.subject.meshFibroblast Growth Factor 2-
dc.subject.meshGene Expression Regulation, Neoplastic-
dc.subject.meshHeparitin Sulfate-
dc.subject.meshHumans-
dc.subject.meshImmunohistochemistry-
dc.subject.meshIn Situ Hybridization-
dc.subject.meshOvarian Neoplasms-
dc.subject.meshProtein Isoforms-
dc.subject.meshRNA, Messenger-
dc.subject.meshReceptor Protein-Tyrosine Kinases-
dc.subject.meshReceptor, Fibroblast Growth Factor, Type 1-
dc.subject.meshReceptors, Fibroblast Growth Factor-
dc.subject.meshReverse Transcriptase Polymerase Chain Reaction-
dc.subject.meshSulfates-
dc.titleRegulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Department of Medical Oncology, Christie Hospital and Paterson Institute, Manchester, United Kingdom.en
dc.identifier.journalClinical Cancer Researchen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.